State-of-the-art facility accelerates clinical trials to commercialisation with international PIC/S GMP-compliant manufacturing processes :

• The new ATP GMP Centre will forge a world-class CGT manufacturing industry in Hong Kong and the Greater Bay Area.
• CUHK collaboration boosts HKSTP’s mission to accelerate translation of scientific discoveries into life-saving biomedical innovations.
• The centre features a highly skilled workforce, cluster development and excellent logistics infrastructure, speeding up CGT development.

With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the opening of a new Advanced Therapy Products (ATP) Good Manufacturing Practice (GMP) Centre earlier this month.

改造一個小小的細胞，可讓癌症治療向前邁進了一大步。近年細胞和基因治療在醫治和預防疾病方面取得革命性進展，然而這些治療方案在香港的價格十分昂貴，令病人難以負擔，而且大多數是在海外生產，過程非常耗時和充滿不確定，不少病人等不及治療就已離世。

創科發展日漸成熟，癌症治療亦邁向科技化。中文大學成立「先進治療產品良好生產規範中心」下月正式啟用，是本港首個製造細胞及基因治療產品的科研機構，以基因改造細胞技術治療癌症、骨骼衰弱等，以往依賴海外完成的基因改造程序，有望改為本地研發，節省時間及成本；中心將與本地兩所醫院合作臨牀治療及研究。校長段崇智指，中心將積極推動生物醫學科技的研究，並歡迎其他院校加入。

CUHK has entered into a new partnership with the Hong Kong Science and Technology Parks Corporation (HKSTP) to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine and related biomedical technologies.

The Chinese University of Hong Kong (CUHK) and Hong Kong Science and Technology Parks Corporation (HKSTP), announce their partnership to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine, and related biomedical technologies.